Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,825 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy.
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group. Kirisawa T, et al. Among authors: miyake m. Int J Clin Oncol. 2023 Feb;28(2):306-313. doi: 10.1007/s10147-022-02278-7. Epub 2022 Dec 17. Int J Clin Oncol. 2023. PMID: 36527579
Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
Miyake M, Morizawa Y, Hori S, Marugami N, Iida K, Ohnishi K, Gotoh D, Tatsumi Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Fujimoto K. Miyake M, et al. Oncology. 2017;93(4):259-269. doi: 10.1159/000477405. Epub 2017 Jun 24. Oncology. 2017. PMID: 28647740
Evaluation of pro‑ and anti‑tumor effects induced by three colony‑stimulating factors, G‑CSF, GM‑CSF and M‑CSF, in bladder cancer cells: Is G‑CSF a friend of bladder cancer cells?
Hori S, Miyake M, Onishi S, Morizawa Y, Nakai Y, Tatsumi Y, Onishi K, Iida K, Gotoh D, Itami Y, Tanaka N, Fujimoto K. Hori S, et al. Among authors: miyake m. Int J Oncol. 2019 Jun;54(6):2237-2249. doi: 10.3892/ijo.2019.4772. Epub 2019 Apr 4. Int J Oncol. 2019. PMID: 31081057
Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.
Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Yamaki K, Hasegawa M, Fujimoto K. Nakai Y, et al. Among authors: miyake m. Jpn J Clin Oncol. 2020 Jan 24;50(1):58-65. doi: 10.1093/jjco/hyz136. Jpn J Clin Oncol. 2020. PMID: 31665354
A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables.
Miyake M, Matsuyama H, Teramukai S, Kinoshita F, Yokota I, Matsumoto H, Shimada K, Kinjyo M, Shimokama T, Okumura K, Yomenori M, Enokida H, Nakagawa M, Nakai Y, Fujimoto K; Nishinihon Uro-oncology Extensive Collaboration group. Miyake M, et al. Int J Clin Oncol. 2020 Jul;25(7):1364-1376. doi: 10.1007/s10147-020-01654-5. Epub 2020 Mar 30. Int J Clin Oncol. 2020. PMID: 32232691
Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.
Kitamura H, Hinotsu S, Tsukamoto T, Shibata T, Mizusawa J, Kobayashi T, Miyake M, Nishiyama N, Kojima T, Nishiyama H; Urologic Oncology Study Group of the Japan Clinical Oncology Group. Kitamura H, et al. Among authors: miyake m. Jpn J Clin Oncol. 2020 Dec 16;50(12):1464-1469. doi: 10.1093/jjco/hyaa123. Jpn J Clin Oncol. 2020. PMID: 32699909 Clinical Trial.
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H; Japanese Urological Oncology Group. Miyake M, et al. BMC Cancer. 2021 Mar 11;21(1):266. doi: 10.1186/s12885-021-07966-7. BMC Cancer. 2021. PMID: 33706705 Free PMC article.
Intravesical Bacillus Calmette-Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies.
Miyake M, Nishimura N, Iida K, Fujii T, Nishikawa R, Teraoka S, Takenaka A, Kikuchi H, Abe T, Shinohara N, Okajima E, Shimizu T, Hori S, Tsuchiya N, Owari T, Murakami Y, Taoka R, Kobayashi T, Kojima T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Miyake M, et al. Cancers (Basel). 2021 May 26;13(11):2615. doi: 10.3390/cancers13112615. Cancers (Basel). 2021. PMID: 34073436 Free PMC article.
1,825 results